For how we live.
In a Canadian cohort of 228 women with HIV, antibody titres matched those of women without HIV and cervical precancer was not recorded — but protection tracked with viral suppression.
A national cohort of 3,584,203 people found that 96.4% of those re-tested still had a viral load below 1000 copies per mL a year later — the threshold at which HIV is not transmitted sexually.
A trial across 24 Zambian clinics found a person-centred care package lifted the share of patients in care a year after a treatment gap from 51.5% to 60.1%, and halved repeat interruptions.
A run of CDC sole-source awards in August 2026 sends millions directly to the health ministries of Ethiopia, Zambia and Ukraine — a bet on host-government ownership of the HIV response by 2030.
Analysing 32,294 viral sequences from 16,428 people, Swiss researchers found 23 fast-growing clusters drove a third of recent transmission growth — evidence molecular surveillance could target the remaining chains.
In the LATA trial across four countries, 0.9% of teens on long-acting cabotegravir–rilpivirine lost viral suppression by 96 weeks, versus 6.4% on daily tablets — a superiority result.
External validation of the PAANTHER decision algorithm in 277 children across four African countries recorded 93.3% negative predictive value and 97.4% sensitivity against a composite reference standard.
4CMenB had shown promise against gonorrhoea in observational data. Randomised, its efficacy was minus 0.5%. In the same field, a once-weekly oral HIV regimen met non-inferiority at 48 weeks.
Most infections end when the immune system clears them. A few have evolved ways to hide, integrate or persist — which is why they can last a lifetime, and why 'cure' means something different for each.
Before October 2023, Palestinian health authorities had documented 50 people living with HIV in Gaza. A viewpoint argues the collapse of testing and treatment has since erased that count entirely.
Seventy-seven thousand fewer children got PEPFAR-supported HIV treatment in 2025 than the year before. UNAIDS warns permanent cuts could mean millions of additional infections and deaths by 2029.
A 23-year genetic-network analysis of 5,094 cases identified 107 molecular super-spreaders, mostly men aged 50-69, with 94.4% living within 2 km of major transport routes.
In women 41 to 50, late perimenopause and postmenopause brought measurable declines in lung volume, with postmenopausal women losing up to 310 mL of FEV1. HIV status didn't change the pattern.
In the LATITUDE trial, monthly cabotegravir–rilpivirine injections cut regimen failure to 22.8% from 41.2% on oral therapy among people with a history of missed doses, prompting an early stop.
The Eighth Replenishment closed at US$12.64 billion against the US$18 billion its own Investment Case tied to 23 million lives saved and 400 million infections prevented by 2029.
Washington intends to provide up to $792 million over five years. Malawi commits the rest — and the money is meant to flow through the government rather than NGOs.
Among 1,000 adults in Mwanza, overnight oximetry found sleep apnea in 17% of people with HIV and 19% without. Excessive daytime sleepiness, oddly, was more common in those without HIV.
The modelling study puts 719,384 people on PEPFAR-funded oral PrEP in 28 African countries at the end of 2024. Most projected infections fall on key populations whose coverage was already under 6%.
The recommendation covers people weighing at least 35 kg and rests on two trials in which lenacapavir cut HIV infections by 100% and 96% against background incidence.
Across 165 clinics in four African countries, HIV testing fell by up to 35% and treatment starts by up to 32%. Most services had not returned to baseline two months after the orders were lifted.
IHME's annual accounting puts development assistance for health at less than half its 2021 peak, with no recovery forecast to 2030. A companion model estimates what that means for tuberculosis.
The guidelines pair the new injectable with a second, quieter recommendation: use simplified rapid diagnostic testing to start and continue long-acting PrEP, rather than more complex assays.
Lenacapavir is the first HIV pre-exposure prophylaxis given every six months. Two phase 3 trials found zero and two infections in the lenacapavir groups against background rates above 2 per 100 person-years.